Antineoplastons A10 and AS2-1 exhibit growth inhibition of cancer cells by diverse modes of action.

We observed antitumor responses within 2-3 weeks of a combination treatment of chemoradiation therapy and antineoplastons A10 and AS2-1 in phase I clinical study being conducted in Kurume University Hospital.

We reviewed 3 clinical cases of advanced cancer (multiple metastatic lung cancer, thalamic glioma and primary lung cancer) in which we believed antineoplaston A10 and AS2-1 may be contributing to the rapid antitumor response.

The possible use of this combination for induction therapy in advanced cancer is discussed.

Tsuda, H. et al. Oncol Rep 1998 May-Jun;5(3):597-600.